Cargando…
The TSP1-CD47-SIRPα interactome: an immune triangle for the checkpoint era
The use of treatments, such as programmed death protein 1 (PD1) or cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) antibodies, that loosen the natural checks upon immune cell activity to enhance cancer killing have shifted clinical practice and outcomes for the better. Accordingly, the number o...
Autores principales: | Montero, Enrique, Isenberg, Jeffrey S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412679/ https://www.ncbi.nlm.nih.gov/pubmed/37217603 http://dx.doi.org/10.1007/s00262-023-03465-9 |
Ejemplares similares
-
The SIRPα–CD47 immune checkpoint in NK cells
por: Deuse, Tobias, et al.
Publicado: (2021) -
Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020) -
Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint
por: Voets, Erik, et al.
Publicado: (2019) -
Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils
por: Behrens, Leonie M., et al.
Publicado: (2022) -
Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment
por: Liao, Haiqin, et al.
Publicado: (2022)